Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results For Vigabatrin In The Treatment Of Cocaine Addiction
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst’s lead compound, CPP-109, is bioequivalent to vigabatrin. [click link for full article]
More: continued here